The efficiency of pharmaceutical R&D is declining. That much is not in doubt: record R&D expenditure in the last decade has led to fewer drug approvals overall, and almost a complete drought in genuine, first-in-class innovation. Set aside biologicals, and … Continue reading
April 18, 2012
by admin
1 Comment